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Recently, myxoma virus was shown to encode an additional member of the serpin superfamily. The viral
gene, called serp2, was cloned, and the Serp2 protein was shown to specifically bind to interleukin-1 (IL-
1)-converting enzyme (ICE), thus inhibiting the cleavage of pro-IL-1 by the protease (F. Petit, S. Bertagnoli,
J. Gelfi, F. Fassy, C. Boucraut-Baralon, and A. Milon, J. Virol. 70:5860–5866, 1996). Here, we address the role
of Serp2 in the development of myxomatosis, a lethal infectious disease of the European rabbit. A Serp2 mutant
myxoma virus was constructed by disruption of the single-copy serp2 gene and insertion of the Escherichia coli
gpt gene serving as the selectable marker. A revertant virus was obtained by replacing the E. coli gpt gene by
the intact serp2 open reading frame. The Serp2 mutant virus replicated with wild-type kinetics both in rabbit
fibroblasts and a rabbit CD4 T-cell line (RL5). Moderate reduction of cell surface levels of major histocom-
patibility complex I was observed after infection with wild-type or Serp2 mutant myxoma virus, and both
produced white pocks on the chorioallantoic membrane of the chick embryo. After the infection of European
rabbits, the Serp2 mutant virus proved to be highly attenuated compared to wild-type myxoma virus, as
demonstrated by the clinical course of myxomatosis and the survival rates of infected animals. Pathohisto-
logical examinations revealed that infection with wild-type myxoma virus resulted in a blockade of the
inflammatory response at the vascular level. In contrast, rapid inflammatory reactions occurred upon infection
with the Serp2mutant virus. Furthermore, lymphocytes in lymph nodes derived from animals inoculated with
Serp2 mutant virus were shown to rapidly undergo apoptosis. We postulate that the virulence of myxoma virus
in the European rabbit can be partially attributed to an impairment of host inflammatory processes and to the
prevention of apoptosis in lymphocytes. The weakening of host defense is directly linked to serp2 gene function
and is likely to involve the inhibition of IL-1-converting-enzyme-dependent pathways.
Virus survival within immunocompetent hosts requires mul-
tiple defensive strategies to evade antiviral and inflammatory
responses. Poxviruses, which are among the largest animal
viruses, have developed specific and efficient strategies, includ-
ing interference with cytokines and growth factors, inhibition
of the complement cascade, reduction of inflammation, and
repression of cellular immune recognition, to effectively prop-
agate within the infected host (3, 38, 47, 57, 60).
The genome of poxviruses is a linear large, double-stranded
DNA molecule, encoding all the enzymes required for repli-
cation and transcription of its DNA, in addition to virulence
factors. Whereas the essential genes are located in the central
part of the genome, the genes responsible for virulence and
host-range (usually not essential) mostly map near the termini
(17, 65, 66). Some viral proteins help circumvent the host
immune response, usually by mimicking cytokines or cytokine
receptors. Poxviruses produce homologues to tumor necrosis
factor (TNF) receptor (27, 56), interleukin-1 (IL-1) recep-
tor (2, 59), gamma interferon (IFN-) receptor (4, 5, 61, 69),
and chemokine inhibitors (25, 55). Poxviruses are also able to
block the production of some important cytokines by inhibiting
the enzymes required for their processing. This is the case for
the Orthopoxvirus genus members, for which SPI-2 protein
(also known as CrmA) is an inhibitor of the IL-1-converting
enzyme (ICE) (33, 48, 50, 58, 64).
Previously, we described the cloning and characterization of
Serp2, a new myxoma virus-encoded serpin protein closely
related to CrmA (46). Myxoma virus (MV), a member of the
genus Leporipoxvirus, is responsible for myxomatosis, a disease
fatal to the European rabbit (Oryctolagus cuniculus). After an
incubation period of a few days following infection, the pri-
mary site of intradermal inoculation evolves as a lesion char-
acterized by tissue degeneration and necrosis. Viral dissemi-
nation leads to a generalization of the symptoms in the skin,
head, and genital region, together with the development of
gram-negative infections of the nasal and conjunctival mucosae
(20, 37). The disease is characterized by general dysfunction of
cellular immunity and multiple interruptions of the host cyto-
kine network, with death as the most common outcome due to
extreme weakness and secondary respiratory tract infections.
A number of MV proteins have been described to function
as virulence factors, including M-T1 (25), M-T5 (39), M-T7
(40), M-T2 (69), SERP-1 (34, 67), M11L (45), and myxoma
growth factor (45); most of these are proteins that interfere
directly with effectors of the host immune system. The impor-
tance of Serp2 to myxoma virus replication in vitro and in vivo
has not been investigated. We report here the characterization
of Serp2 as another critical virulence factor of MV. Disruption
of the Serp2 open reading frame resulted in an MV mutant
that replicated normally in vitro and in vivo but was highly
attenuated upon infection of European rabbits. Loss of MV
virulence was correlated with marked increase of inflammatory
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and apoptotic responses in animals inoculated with Serp2
mutant virus. These in vivo findings are well explained by the
results from our previous in vitro experiments suggesting that
Serp2 can specifically inhibit ICE.
MATERIALS AND METHODS
Cells and viruses. The MV strains T1 and Lausanne, the Serp2 mutant virus,
the Shope fibroma virus (SFV), the vaccinia virus MVA, and the recombinant
vaccinia virus MVA-HIV-nef were grown in the rabbit kidney cell line RK13
maintained in Dulbecco’s minimum essential medium supplemented with 10%
fetal calf serum. The revertant MV-Serp2 rev was selected in HGPRT HeLa
cells (30). Rabbit CD4 T lymphocytes, RL5 (29), were maintained in RPMI
1640 (Gibco BRL) supplemented with 10% fetal calf serum.
Construction of MV-Serp2 mutant and revertant viruses. The MV serp2
gene was cloned into the Bluescript phagemid expression vector as described
previously (46). DNA of this plasmid was used as template to PCR amplify the
DNA fragments MV-serp2L and MV-serp2R. The following primers were used:
5serp2-1 5-XhoI-CAG CTC GAG CGT CGG CAG TCT TCG TTT CTC
CCCG-3; 5serp2-2 5-PstI-CAG CTG CAG GCC CTC GTT CCT CAC GTC
CACG-3, 3serp2-1 5-ClaI-CAG ATC GAT CCC GTA CGA GTA CGG GTA
CTCC-3, and 3serp2-2 5-SacI-CAG GAG CTC CGC GTA CGG GGG ACT
GTT TAA ACG CG-3. Amplified MV-serp2L and MV-serp2R DNA was di-
gested with XhoI/PstI and ClaI/SacI, respectively, and inserted into pRBgpt
flanking an expression cassette containing the Escherichia coli guanosine phos-
phoribosyltransferase (gpt) gene under the control of the vaccinia virus early-late
promoter 7.5K (18). The resulting plasmid, called pserp2:gpt, was used for trans-
fection into MV-infected cells. MV-Serp2mutant MV was isolated selecting for
resistance against mycophenolic acid (19).
An MV-Serp2 rev revertant virus containing a wild-type Serp2 open reading
frame was constructed by transfecting plasmid DNA containing the complete
serp2 gene into MV-Serp2-infected RK13 cells and by using reverse gpt selec-
tion on HeLa cells (28) to isolate revertants. PCR and Southern blot analysis of
viral DNA was used to confirm the disruption of the Serp2 open reading frame
by insertion of the p7.5 gpt expression cassette, the absence of detectable wild-
type virus in preparations of MV-Serp2 mutant virus, and the restoration of the
serp2 gene in MV-Serp2 rev revertant virus. Immunoprecipitation of labeled
proteins with anti-Serp2 antibodies was used to confirm the presence of a 34-kDa
protein in extracts of cells infected with the wild-type or the MV-Serp2 rev
revertant viruses, as well as the absence of any specific protein in extracts from
MV-Serp2 mutant virus-infected cells.
Single-step growth analysis in cell culture. RL5 cells (5  105) were infected
with MV strain T1 or MV-Serp2 at a multiplicity of infection of 5 for 2 h.
Unadsorbed free virus was removed, cells were washed with serum-free medium
three times, growth medium was added, and cells were incubated at 37°C.
Cultures were harvested at multiple time points postinoculation, and virus was
released by freeze-thawing and brief sonication. Virus titers in these lysates were
determined by standard plaque titration on RK13 cells monolayers. Single-step
growth experiments were performed in triplicate.
Apoptosis assays. To determine whether Serp2 could inhibit TNF--mediated
apoptosis, 2 104 HeLa cells in microtiter plates were infected with wild-type or
MV-Serp2 MV at a multiplicity of infection of 100, in RPMI containing 10 	M
BrdU (bromodeoxyuridine). At 15 h postinfection, the cells were rinsed twice
and fresh medium supplemented with serum was added. TNF- (10 ng/ml;
Boehringer-Mannheim) and cycloheximide (40 	g/ml; Sigma) were added, and
apoptosis was assessed 8 h later by cellular DNA fragmentation enzyme-linked
immunosorbent assay (ELISA) (Boehringer-Mannheim) according to the rec-
ommendations of the manufacturer. The cells were harvested by the addition of
lysis buffer, which leads to a release of fragmented DNA from the cytoplasm to
the supernatant. After an incubation of 30 min at room temperature, followed by
a centrifugation at 250  g for 10 min, the supernatants were transferred to an
ELISA plate precoated with anti-DNA antibodies, and the amount of BrdU
present in each sample was determined by using anti-BrdU peroxidase conjugate
solution and its substrate with a spectrophotometer at 450 nm. Mock-infected
cells, in the presence of TNF- and cycloheximide, were used as a positive
control, and cells cultured for 8 h with cycloheximide in the absence of TNF-
were used as a negative control.
Antibody binding and flow cytometry analysis. RL5 cells (2  106) were
infected with MV strain T1, MV-Serp2, MV strain Lausanne, SFV, vaccinia
virus MVA, or recombinant vaccinia virus MVA-HIV-nef at a multiplicity of
infection of 5 for 2 h. Unadsorbed virus was removed, and the cells were washed
with serum-free medium three times and then with medium supplemented with
serum; the cultures were then harvested at 24 h postinfection. Cells were rinsed
twice in RPMI supplemented with 1% serum and resuspended in 100 	l RPMI
or binding buffer (137 mM NaCl, 12 mM NaHCO3, 2.6 mM KCl, 2 mM MgCl2,
5.6 mM glucose; pH 7.4) (11). CD4 monoclonal antibodies (Spring Valley Lab-
oratories) were added at a concentration of 25 	g/ml to the cells in RPMI, and
class I major histocompatibility complex (MHC) monoclonal antibodies (Spring
Valley Laboratories) were added at a concentration of 25 	g/ml to the cells in
binding buffer. After an incubation of 20 min at 4°C, the cells were rinsed in
RPMI before addition of fluorescein isothiocyanate-conjugated goat anti-mouse
antibody. The mixture was incubated for a further 20 min at 4°C. The cells were
then rinsed twice in RPMI and resuspended in phosphate-buffered saline for
analysis on a fluorescence-activated cell sorter Calibur flow cytometer (Becton
Dickinson). Data were acquired from 20,000 cells and analyzed with CellQuest
software. Experiments using isotypic immunoglobulin G1 were used as nonspe-
cific binding controls. Analysis with all antibodies and all viruses were performed
in triplicate.
Infection of rabbits with MV-Serp2 mutant virus. Eight-week-old male New
Zealand White rabbits (Oryctolagus cuniculus) were obtained from a local sup-
plier and housed in biocontainment facilities under the guidelines of the Euro-
pean Community Council on Animal Care. Injections were performed intrader-
mally in the right ear with 5  103 PFU of virus per animal. Rabbits which
became moribund were sacrificed after anesthetization with T61 (Distrivet) ad-
ministered intravenously. For histological studies, six rabbits each were inocu-
lated with MV T1 strain or MV-Serp2 as described above. At 4, 8, and 11 days
postinoculation, two animals from each group were sacrificed. Two mock-in-
fected rabbits were sacrificed and used as controls.
Histological examination. All animals were subjected to a complete postmor-
tem examination. Tissue material from the injection site (ear; primary site) and
ocular conjunctiva, parotid lymph node, spleen, lungs, and testis were taken and
stored in 10% neutral formalin for further analysis. After fixation, tissues were
processed routinely into paraffin blocks, sectioned at 4 	m, and stained with
hematoxylin and eosin for microscopic examination. Histologic lesions were
assessed and graded as follows: , minimal; , light; , moderate;
, marked; and , severe. The TUNEL method was used to assess
apoptosis of lymphocytes in parotid lymph nodes and spleen. For this reaction,
two thymuses of young mice treated with corticoids were used as positive con-
trols. Conventional histologic sections, pretreated with 20 	g of proteinase K per
ml (Boehringer-Mannheim) for 15 min at 37°C, were incubated with digoxigenin-
labeled dUTP and terminal deoxytransferase (ONCOR), according to the rec-
ommendations of the manufacturer. The samples were stained using anti-
digoxigenin peroxidase-conjugated antibodies. The localized peroxidase then
catalytically generated a signal from a chromogenic substrate (3,3-diaminoben-
zidine with nickel). The following form of grading, based on the number of
apoptotic bodies for each microscopic field at a400 magnification, was used:,
minimal apoptosis, 25 to 50 apoptotic bodies; , light apoptosis, 50 to 75
apoptotic bodies; , moderate apoptosis, 75 to 100 apoptotic bodies;
, marked apoptosis, 75 to 100 apoptotic bodies; and , severe
apoptosis, 125 to 150 apoptotic bodies.
Immunostaining of histologic sections. Viral antigens in paraffin-embedded
sections of ear (primary site) and parotid lymph node were reactivated by using
0.1% trypsin in phosphate-buffered saline (pH 7.6) for 30 min at 37°C. After
neutralization of endogenous peroxidase and before incubation with the specific
primary antibody (rabbit hyperimmune serum anti-MV), the samples were in-
cubated in goat preimmune serum. This step was performed in order to minimize
the background generated by the secondary antibody (biotinylated goat anti-
rabbit immunoglobulin G) provided by Dako (kit K492). Horseradish peroxi-
dase-streptavidin complex was added and revealed by DAB (3,3-diaminobenzi-
dine tetrahydrochloride), which formed a brown precipitate. Nuclei were
counterstained with Mayer’s hematoxylin.
RESULTS
Construction and characterization of MV-Serp2 mutant
and revertant. The Serp2 open reading frame is present as a
single-copy gene in the MV genome (46) located within the
EcoRI-F restriction fragment. To construct MV mutant virus,
we disrupted the Serp2 open reading frame by targeting inser-
tion of the Ecogpt marker gene under the control of the vac-
cinia virus p7.5 promoter by homologous recombination pre-
cisely to a site within the Serp2 coding sequence, resulting in a
30-bp deletion in the coding sequence. Using a standard dom-
inant selection method (12, 19, 68), we isolated an MV-Serp2
mutant virus able to replicate in the presence of mycophenolic
acid. As a control we constructed a revertant virus derived
from MV-Serp2 in which the complete Serp2 open reading
frame was restored and which was referred to as MV-Serp2 rev.
To ensure correct disruption of the serp2 gene and its authentic
restoration in MV-Serp2 rev, viral DNA was analyzed by PCR
with the specific primers 5serp2-1 and 3serp2-2. Agarose gel
electrophoresis of DNA amplified from wild-type- andMV-Serp2
rev-specific template DNA revealed fragments corresponding in
size (1,130 bp) to the expected molecular weight of the complete
Serp2 coding sequence (data not shown). In contrast, a DNA
fragment of 2,850 bp could be amplified from MV-Serp2 DNA,
which indicated the presence of additional genomic sequence due
to the integration of the gpt expression cassette. Furthermore, this
analysis confirmed the genetic purity of MV-Serp2mutant virus
as shown by the failure to amplify a detectable DNA band cor-
responding in size to the wild-type Serp2 coding sequence. Addi-
tionally, Southern blot analysis of viral DNA revealed character-
istic restriction patterns for the wild-type, MV-Serp2, and MV-
Serp2 rev genomes (data not shown). Since only 30 bp of the serp2
open reading frame were missing, we wanted to make sure that
the protein could not be produced, even as a truncated form.
Immunoprecipitation with a specific anti-Serp2 antiserum (46)
revealed a polypeptide of 34 kDa, corresponding to Serp2, in
extracts from RK13 cells infected by either the wild-type or the
MV-Serp2 rev virus, but no specific band could be visualized on
extracts from cells infected with theMV-Serp2mutant (data not
shown).
Comparison of pocks formed on the chorioallantoic mem-
brane. The chorioallantoic membrane (CAM) of chick em-
bryos has been widely used to study the acute inflammatory
response to poxvirus infection. In that system the wild-type
cowpox virus produces hemorrhages, whereas a mutant lacking
the crmA gene produces white pocks characterized by an influx
of inflammatory cells (22, 48). To compare the lesions pro-
duced on CAM, 9-day-old embryonated eggs were infected
with 105 PFU of wild-type MV or MV-Serp2 mutant. After 5
days of incubation at 33°C, an examination of the CAM re-
vealed small white pocks (ca. 1 mm in diameter) which were
present on CAM infected with either virus. No hemorrhage
was detected. Furthermore, the pocks formed by both viruses
did not differ in number or other morphology.
MV-Serp2 mutant efficiently replicates in rabbit kidney
cell and CD4 T-cell lines. No defects in the ability of MV-
Serp2 to replicate in cultured rabbit RK13 fibroblasts in vitro
were noted in a single-step growth curve analysis. Similar re-
sults were also found in a cultured rabbit RL5 CD4 T-cell line
(data not shown).
MV-Serp2 mutant fails to induce apoptosis upon cell cul-
ture infection. Since we have demonstrated previously that
Serp2 exhibits ICE inhibiting activity and that the ICE family,
recently named the caspases, plays a central role in the execu-
tion of apoptosis, we were interested in investigating apoptotic
cell death after infection with MV-Serp2 mutant virus.
Since MV-Serp2 could replicate with wild-type kinetics in
RL5, these cells were not expected to be a good model for
investigating an antiapoptotic role for Serp2. Indeed, when
using DNA fragmentation ELISA, we found no apoptosis in
RL5 cells, infected with either wild-type or MV-Serp2 MV.
MV-Serp2 mutant virus inhibits TNF--mediated apopto-
sis. In a similar way we also studied HeLa cells, which are
susceptible to TNF--mediated apoptosis. We measured the
cellular DNA fragmentation (ELISA test) after infection with
wild-type MV or MV-Serp2 and after treatment with TNF-
and cycloheximide. Mock-infected cells, in the absence of
TNF-, showed no sign of apoptosis. Incubation with TNF-
and cycloheximide induced apoptosis, as measured 8 h after
treatment. There was no significative apoptosis in cells infected
with wild-type MV. The results were the same with cells in-
fected with MV-Serp2, indicating that Serp2 is not necessary
for the inhibition of TNF-induced apoptosis in HeLa cells
(data not shown).
Effect of Serp2 on the level of cell surface antigens. Since it
has been shown that there is a decrease of the class I MHC
surface expression at 24 h after infection with MV strain Lau-
sanne (11), we investigated whether disruption of the Serp2
open reading frame could influence the expression of these
antigens at the cell surface. Having checked that mock-infected
RL5 cells showed strongly positive surface staining with mono-
clonal antibody against the class I MHC, we saw no striking
difference in the downregulation of MHC I on the surface of
RL5 cells infected with wild-type MV strain T1 or with MV-
Serp2 mutant virus (data not shown). These results suggest
that Serp2 is not implicated in the downregulation of MHC I
antigens on the surface of T-lymphocyte cells.
It has also been published that upon infection with MV, the
level of CD4 surface antigens was markedly reduced (8). In a
similar way, we also investigated the influence of serp2 disrup-
tion on the described phenotype. Mock-infected RL5 cells
showed a strong positive surface staining with anti-CD4 anti-
bodies. After infection with wild-type MV strain T1 or Lau-
sanne, there was a slight decrease in surface CD4 levels; the
same observation could be made after infection of RL5 cells
with MV-Serp2 mutant. Infection of RL5 cells with vaccinia
virus expressing HIV-nef led to a severe downregulation of
CD4 molecules and served as a positive control (data not
shown). These results suggest that Serp2 has no impact on the
downregulation of CD4 antigens on the surface of RL5 cells.
MV-Serp2 is an important virulence factor in the European
rabbit. European rabbits infected with wild-type MV (strain
T1 or Lausanne) rapidly develop a routinely 100% fatal disease
known as myxomatosis. As well as being able to activate
CPP32, an important cell death protease, ICE is known to
liberate bioactive IL-1, a proinflammatory lymphokine that
can alert neighboring cells of the immune system. This signal-
ing may allow inflammatory cells to activate and accumulate at
FIG. 1. Clinical course of rabbits at 10 days postinoculation. Rabbits infected
with the wild-type MV (A and B) show secondary skin lesions turning necrotic on
the head, the back, and the legs and edema of the testicles (A) and show primary
and secondary myxomas on the ears, leading to abnormal posture, and on the
nose and around the eyes, and blepharoconjunctivitis (B). Rabbits infected with
the MV-Serp2 mutant (C and D) show no secondary skin lesions and little
edema of the genital region (C); they also show marked diffuse inflammation of
the ears and blepharoconjunctivitis (D).
a site where cell suicide is being used as an antiviral defense
(70). Therefore, the putative anti-ICE activity of Serp2 tempt-
ed us to determine the effects of a serp2 disruption on MV
virulence in vivo. Three groups of animals were infected with
wild-type MV (n 
 4), MV-Serp2 mutant virus (n 
 10), or
MV-Serp2 rev (n 
 4). We observed a marked reduction in
virulence in rabbits infected with MV-Serp2 compared to
rabbits infected with wild-type MV or MV-Serp2 rev, respec-
tively (Table 1). On day 4 postinfection, the inoculation site
was a diffuse inflammation in rabbits infected with MV-
Serp2, larger and less circumscribed than in rabbits infected
with wild-type MV or MV-Serp2 rev, in which a red and soft
nodule, known as the primary myxoma, was present. At day 7
postinfection, when rabbits inoculated with either wild-type
MV or MV-Serp2 rev demonstrated classical symptoms of myx-
omatosis and were prostrated, rabbits infected with MV-
Serp2 had no skin lesions, such as secondary myxomas, on the
head, body, or legs. They behaved normally and presented only
a mild conjunctivitis. The ears were thickened and red. By day
11 postinfection, all eight rabbits infected with wild-type MV
or MV-Serp2 rev had to be sacrificed, whereas in MV-Serp2-
infected rabbits, clinical signs of gram-negative infections in
the conjunctiva and respiratory tract had developed, although
the usual state of health remained unchanged (Fig. 1). The
respiratory symptoms worsened between days 10 and 15, but
no classical myxomas were observed. Seven of ten animals
infected with MV-Serp2 mutant virus completely recovered
within 30 days. Only three rabbits had to be sacrificed because
of respiratory infection (on days 14, 15, and 25), which yields
an overall survival rate of 70% in animals infected with MV-
Serp2 virus. In contrast, a 100% mortality was found in both
groups of control rabbits.
Histologic analysis of lesions from wild-type virus and MV-
Serp2-infected rabbits. In view of the significant difference in
virulence of the MV-Serp2 mutant and the wild-type MV, we
performed a more detailed histologic examination of tissue
material taken from both primary (ear) and secondary (ocular
conjunctiva and parotid lymph node) infection sites at various
times during the course of infection. Other sample sites
(spleen, lungs, and testis) were realized to detect possible his-
tologic lesions linked to a systemic spread of the virus. In all
animals, no lesion was observed in these tissues, whatever the
time after infection. The results of the complete analysis are
summarized in Table 2.
At day 4 postinoculation, the injection site of animals in-
fected with wild-type MV demonstrated a light perivascular
dermatitis with focal edema and scattered heterophils. At the
site of injection of the MV-Serp2 mutant, the inflammatory
response was qualitatively the same but was less intense. A
superficial perivascular conjunctivitis was present in each case,
though slightly more pronounced for the wild-type virus. It
should be noted that one rabbit inoculated with MV-Serp2
mutant showed a light lymphodepletion, while small lympho-
nodules were present in the lamina propria of the ocular con-
junctiva in all other rabbits.
In the parotid lymph nodes, lesions induced by the two types
of viruses differed significantly. A marked lymphadenitis with
histiocytosis and infiltration by heterophils was seen after in-
fection with the wild-type MV, whereas the lesions caused by
MV-Serp2 mutant virus were characterized by extensive focal
depletions of lymphocytes. The latter finding could well be the
consequence of vigorous cell death triggered by the viral in-
fection even if this process cannot be determined on conven-
tional histologic sections.
At day 8 postinoculation, the differences in the resulting patho-
logic pattern became even more evident. In primary sites, the
lesions associated with the wild-type virus were a marked perivas-
cular dermatitis with diffuse edema, focal interstitial hemor-
rhages, accumulation of heterophils, and a well-developed myx-
oma (i.e., activated fibroblasts and interstitial mucinosis). In
contrast, the lesions associated with the MV-Serp2 mutant pre-
sented two striking differences: they were much less intense, and
the sequential inflammatory cellular reactions progressed more
rapidly, as attested to by the presence of infiltrates of mononu-
clear cells (histiocytes and lymphocytes). These observations are
also valid for the conjunctival lesions. The parotid lymph nodes of
rabbits inoculated with the wild-type MV showed a marked
lymphadenitis with secondary myxomas. The parotid lymph nodes
of rabbits inoculated with MV-Serp2 mutant exhibited a severe
lymphodepletion and no secondary myxoma was observed.
TABLE 1. Pathogenicity of MV-Serp2 in European rabbits
Day
Virulence effects of:
Wild-type MV and MV-Serp2 reva MV-Serp2 mutantb
0 Inoculation of four rabbits with wild-type MV strain T1 and four rabbits
with MV-Serp2 rev intradermally with 5,000 PFU
Inoculation of 10 rabbits intradermally with 5,000 PFU
4 Primary lesions at inoculation sites: raised, soft, red, ca. 2 cm Primary lesions at inoculation sites: red, diffuse, ca. 3
cm
7 Emaciated; prostrated; gram-negative bacterial infections of nasal and
conjunctival mucosa; multiple secondary lesions on face and ears;
edema of the testicles
Normal fatness; regular activity; mild conjunctivitis; no
gram-negative bacterial infections detected; diffuse
inflammation of the ears
11 Emaciated; ataxia; dyspnea; severe gram-negative bacterial infections in
conjunctiva and respiratory tract; secondary lesions turning necrotic;
all rabbits sacrificed because of increased severity of the symptoms
Regular activity; purulent blepharoconjunctivitis and
nasal discharge; marked inflammation of the ears;
no secondary myxomas (6/10) or minute myxomas
on the back and nose (4/10)
15 Gram-negative bacterial infections of nasal and
conjunctival mucosa; no secondary or minute
myxomas; one rabbit sacrificed at day 14; one rabbit
sacrificed at day 15
30 Full regression of the symptoms, except for one rabbit
sacrificed at day 25 due to respiratory bacterial
infection
a Rabbit survival: 0 of 4 and 0 of 4.
b Rabbit survival: 7 of 10.
At day 11, the same major differences were noted, and some
features must be pointed out: (i) a severe infiltration by het-
erophils persisted at the primary sites of infection with the
wild-type virus, whereas for the MV-Serp2 mutant, mononu-
clear cells were predominant (Fig. 2); (ii) well-developed sec-
ondary myxomas were seen only in secondary sites of rabbits
inoculated with wild-type MV; and (iii) a severe lymphodeple-
tion was present only in the parotid lymph node of MV-Serp2
mutant-inoculated rabbits.
From these observations we can conclude that the inflam-
matory reaction is far less hemorrhagic and more rapidly pro-
gressive in lesions induced by the MV-Serp2 mutant. This
virus leads to a progressive, severe lymphodepletion in the
parotid lymph node. No secondary myxoma was seen in the
secondary sites.
Histologic assessment of lymphoid apoptosis. The TUNEL
method was used to assess apoptosis of lymphocytes in the pa-
rotid lymph node and spleen of 12 inoculated rabbits and 2 con-
trol animals. The main results for the parotid lymph node are
summarized in Table 3. The two controls showed minimal apo-
ptosis (25 to 50 apoptotic bodies for each microscopic field at a
400 magnification), mainly located in the germinal centers. For
rabbits inoculated with wild-type MV, apoptosis of lymphocytes
was at the same level and showed the same localization as con-
trols, whatever the day of the experiment (Fig. 3A). The foci of
apoptotic heterophils were seen; they could be easily distin-
guished from apoptotic lymphocytes by cytologic criteria.
The parotid lymph nodes of rabbits inoculated with the MV-
Serp2mutant underwent apoptosis, with major differences from
the controls: at day 4 postinoculation, a focal extensive apoptosis
was initiated in an area of the lymph node (Fig. 3B and C). The
grade of the two rabbits was different (light versus severe). Foci of
apoptotic heterophils were also seen. At day 8 postinoculation,
the parotid lymph node of both rabbits showed a severe focal
extensive apoptosis. At day 11, large areas of the parotid lymph
node contained only remnants of apoptotic bodies for each ani-
mal (Fig. 3D). Traces of localized extensive foci persisted. In
intact remaining lymphoid tissue, a light increase in the number of
apoptotic lymphocytes was noticed.
From these results we conclude that lymphodepletion in the
lymph node draining the primary site is imputable to apoptosis
of lymphocytes. Apoptosis of lymphocytes in the spleen was the
same in rabbits injected either with the wild-type MV or with
the MV-Serp2 mutant and was identical to the controls.
Virus load in tissues. In order to make sure that the striking
phenotypic differences between the wild-type and the MV-
Serp2mutant could not be attributed to an impairment of the
latter virus to replicate in vivo, we quantified the level of viral
replication at the inoculation site and the parotid lymph node.
Standard immunohistochemical studies were carried out, and
the levels of virus replication in tissues stained with anti-MV
antibodies were quantified by counting the number of infected
cells per square millimeter.
At days 4, 8, and 11 postinoculation, there was the same level
of virus replication at the injection site of either the wild-type or
the MV-Serp2 mutant (not shown); comparable results were
TABLE 2. Histologic observations of lesions from rabbits infected with the wild-type MV or the MV-Serp2 mutant
Site
Lesion intensity (lesion topography)a at:
Day 4 p.i. Day 8 p.i. Day 11 p.i.
Wild type MV-Serp2 Wild type MV-Serp2 Wild type MV-Serp2
Primaryb
Perivascular dermatitis with:
Epidermal spongiosis and vesicles   (f)  
Edema  (f)  (f)  (d)   (d)  (d)
Focal interstitial microhemorrhage    
Focal thrombosis 
Inflammatory infiltrates of:
Heterophils (perivascular and interstitial)  (s)    (s)   (s)
Histiocytes, lymphocytes (interstitial)   (s) 
Activated fibroblasts      
Interstitial mucinosis      
Secondaryc
Superficial perivascular conjunctivitis with:
Inflammatory infiltrates of:
Heterophils  (f)   (f)  (s)  (m)  (s)
Mononuclear cells (histiocytes, lymphocytes)  (s) 
Focal lymphoid hyperplasia  
Focal lymphoid depletion 
Activated fibroblasts    
Interstitial mucinosis    
Lymphadenitis with:
Lymphodepletion  (f)  (m)  (e)
Focal microhemorrhage 
Focal histiocytosis    (e)   (e) 
Infiltration by heterophils     (s)   (s)
Activated fibroblasts  
Interstitial mucinosis  
a Lesion intensity: , minimal; , light; , moderate; , marked; , severe. Lesion topography: s, scattered; f, focal; m, multifocal; e, extensive;
d, diffuse. p.i., postinoculation.
b Samples were taken from lesions at the inoculation site.
c Samples were taken from lesions on the ocular conjunctiva and parotid nodes.
.
obtained in the parotid lymph node (Fig. 4). Eight days after
infection with the wild-type MV, the cells in the lymph node
(mostly fibroblasts and histiocytes, which are characteristic of the
secondary myxomas) were positively stained with the anti-MV
antibodies (Fig. 4A). With the MV-Serp2 mutant, the cell pop-
ulations were different (mostly mononuclear cells, which from
morphologic criteria could be defined as lymphocytes), but the
viral load, according to our semiquantitative measure, was on the
same order of magnitude (Fig. 4B). From these results we con-
clude that the MV-Serp2 mutant is able to replicate in vivo at a
level comparable to that of the wild-type MV.
DISCUSSION
In this study we report data to elucidate the functions of the
MV Serp2 protein, which is 35% identical to the cowpox virus
CrmA protein. CrmA has been characterized as viral inhibitor
of ICE (caspase 1), which can prevent the onset of both in-
FIG. 2. Hematoxylin and eosin-stained skin samples from rabbits at 11 days postinoculation with wild-type MV (A and C) or with MV-Serp2 mutant (B and D).
Magnification: 40 (A and B); 200 (C and D). The panels show perivascular dermatitis with diffuse edema, thrombosis and perivascular accumulation of heterophils
(A); perivascular dermatitis with a less-severe edema and interstitial infiltrates of mononuclear cells (B); severe perivascular and interstitial accumulation of heterophils
(C); and interstitial infiltrates of mononuclear cells (C).
TABLE 3. Histologic assessment by the TUNEL method of lymphoid apoptosis in the parotid lymph nodes of rabbits infected with wild-type
MV or MV-Serp2 mutant
Day
Histologic assessment (lesion intensity)a
Wild-type MV-Serp2
4 A few apoptotic cells in germinal centers (as in controls). Focal extensive apoptosis.
Score: homogeneous () Score: variable (/).
8 A few apoptotic lymphocytes in germinal centers (as in controls). Focal extensive lymphoid apoptosis.
Score: homogeneous () Score: homogeneous ().
11 A few apoptotic lymphocytes in germinal centers (as in controls). Large foci of remnants of apoptotic bodies.
Score: homogeneous () Score: homogeneous ().
Residual focal extensive apoptosis.
Score: homogeneous ().
Extension of apoptosis in remaining
lymphoid tissue.
Score: homogeneous ().
a Lesion intensity: , minimal; , light; , moderate; , marked; , severe.
flammation and apoptosis by reducing the levels of the active
proinflammatory lymphokines IL-1 and IL-18 and by prefer-
entially inhibiting the proximal components of the ICE/CED-3
protease cascade in the cell death process (33, 48, 50, 58, 64).
CrmA also has a high affinity for caspase 8 or FLICE (72) and
Granzyme B (49). More importantly, Serp2 was also previously
shown to bind to human ICE and prevent it from processing
the pro-IL-1 into its bioactive form (46). Therefore, Serp2
FIG. 3. Parotid lymph node (TUNEL method). The panels show samples at 8 days postinoculation with the wild-type MV, with minimal lymphocytic apoptosis (A),
and infection with the MV-Serp2 mutant at 4 days postinoculation, with focal extensive lymphocytic apoptosis in cortical areas (arrows) (B); at 4 days postinoculation,
with focal extensive lymphocytic apoptosis at a higher magnification (C); and at 11 days postinoculation, with remnants of apoptotic foci in a lymphodepleted
parenchyma (arrow) (D). Magnification: 100 (A); 40 (B); 100 (C); 40 (D).
FIG. 4. Parotid lymph node (immunohistochemistry) from rabbits at 8 days postinoculation (400). Infected cells are visualized with DAB (arrow). (A) Infection
with the wild-type MV. The cells present in the lymph node are mostly histiocytes and activated fibroblasts (large nucleus, double arrows). These and other cells are
infected. (B) Infection with the MV-Serp2 mutant. Most cells are infected, and mononuclear cells are predominant.
was another candidate poxvirus-encoded factor to counteract
host defenses and to potentially contribute to the pathology
associated with MV infection.
To assess the role of Serp2 in the pathogenesis of myxoma-
tosis, we successfully engineered a fully replication-competent
MV mutant deleted in the Serp2 open reading frame. Reveal-
ing a wild-type-like phenotype when grown in vitro, the mutant
virus was found to be highly attenuated upon in vivo infection
in rabbits. The clinical course of infection with MV-Serp2
mutant was characterized by the development of mild and
more-diffuse primary myxoma lesions at the site of inoculation,
the absence or benignity of rare secondary lesions and, most
impressively, by the high rate of complete recovery seen in the
infected animals.
Detailed histologic examination led to three major findings.
First, the inflammatory response upon inoculation with wild-
type MV seemed to be arrested at the vascular level (with
heterophils predominant even at a late time), whereas with the
MV-Serp2 mutant the inflammation proceeded to the cellular
phase (with lymphocytes and histiocytes infiltrating the lesion).
In this latter case the overall reaction was less intense and less
hemorrhagic than when Serp2 was present. The inhibition of
IL-1 processing by Serp2 is in accordance with these obser-
vations. IL-1 is a potent proinflammatory cytokine that can
affect the function of many physiologic systems (for a review,
see reference 15). Among the pleiotropic effects of IL-1,
including thrombosis and inflammation, is an increased expres-
sion of the immunoglobulin superfamily molecules ICAM-1
and VCAM-1, which bind to integrins on lymphocytes and
monocytes (14, 24). By blocking IL-1 processing, Serp2 would
diminish the ability of these cells to migrate into the inflamed
tissue. Moreover, ICE is involved in the processing of pro-
IL-18 into its active form (23, 26). IL-18, also known as IFN-
-inducing factor, stimulates the production of IFN- by lym-
phocytes (42, 44). As for IL-1, the effects of IFN- are
numerous, including the chemoattraction of macrophages (10,
43, 71). This phenomenon was also occurs after infection with
a mutant lacking a secreted homolog of the IFN- receptor;
Mossman et al. (40) reported that infection with the IFN-
receptor-deficient MV resulted in an inversion of the hetero-
phil/mononuclear cell ratio at the secondary sites. Our histo-
logic findings, although not definitely proving which cytokine
defect is involved, are consistent with the hypothesis that the
presence of Serp2 leads to a reduced amount of both IL-1
and IFN- at the infection sites.
Our second important histologic observation was that lym-
phocytes, in the absence of Serp2, undergo apoptosis which
can be quantified in the parotid lymph nodes. According to the
spatial distribution of the apoptotic foci in the lymph nodes, it
is reasonable to assume that apoptosis occurred in the lymph
node itself, as well as in lymphocytes drained from the inocu-
lation site. ICE has been widely recognized as an important
mediator of the apoptotic process (reviewed in references 7
and 41). The impairing of ICE by Serp2 would be in accor-
dance with an inhibition of the apoptotic process by the wild-
type virus, but not by the MV-Serp2 mutant virus. However,
in our in vitro experiments, the defect in Serp2 production did
not lead to apoptosis of RL5 T-helper lymphocytes. This cell
line has been widely used to study other MV genes. MV lack-
ing the TNF receptor homologue (53), the M11L-gene (35),
and the host-range superfamily member M-T5 (39) have all
been shown to induce apoptosis in this cell line. The reason
why all these mutants display the same phenotype in RL5 cells
is not clear. M-T5 might counteract the shutoff of protein
synthesis after MV infection (39), but M-T2 does probably not
block apoptosis via its TNF binding domain (53). M11L is a
transmembrane protein involved in the repression of inflam-
mation, but its target is unknown (43). On the other hand, the
cell-type dependence of apoptosis inhibition by viral products
has been widely reported (6, 13, 21, 51). In that context, it is
clear that RL5 cells are not the best model for checking Serp2
inhibition of ICE-mediated apoptosis.
There are several reports that either cowpox CrmA (62) or
its homologue vaccinia virus SPI-2 protein (16, 32) can inhibit
Fas-mediated apoptosis. However, in our experiments Serp2
was not required for the inhibition of TNF-induced apoptosis
in HeLa cells. Several hypotheses underlie our findings. The
first possibility is that, although reported to be unable to bind
to human TNF- (52), the MV TNF receptor homologue was
responsible for this inhibition; another possibility is that there
exists an as-yet-unidentified antiapoptotic factor encoded by
MV, whose role would be to prevent TNF-induced apoptosis.
It has recently been shown that the MC159 protein of Mollus-
cum contagiosum, another member of the poxvirus family,
could inhibit Fas- and TNFR1-induced apoptosis through its
death effector domain (9). It is thus possible that MV encodes
one or more proteins that would prevent ICE activation in cell
culture.
Since it has been reported that MV could downregulate the
expression of CD4 (8) and MHC I molecules (11) on the
surface of infected cells, we checked whether Serp2 could
account for this phenotype. In fact, we could see no difference
in the relative decrease of either CD4 or MHC I antigens of
RL5 cells infected with the wild-type or the MV-Serp2 mu-
tant. The effect of MV on the expression of these surface
molecules was light in both cases compared to the more drastic
effect observed upon the vaccinia virus-mediated expression of
the human immunodeficiency virus type 1 nef gene (1, 54). It
was particularly relevant to check for a possible implication of
Serp2 in MHC I downregulation, since this would have inter-
fered with the apoptosis process. Any decrease in MHC I
expression at the surface of infected cells would result in the
inability of the cytotoxic T lymphocytes to bind to these cells
and to recognize them as targets. Since Serp2 is not interfering
with MHC I expression, the marked difference in the lympho-
cyte apoptosis observed in vivo cannot be attributed to a mod-
ification of the immune effectors on the membrane of the
infected cells. More likely, the difference is due to an antiapop-
totic effect of Serp2.
The last histologic finding was that in the secondary sites
(ocular conjunctiva and lymph nodes) there were no so-called
secondary myxomas upon infection with the MV-Serp2 mu-
tant, contrasting with the wild-type MV. The molecular mech-
anism by which MV induces the formation of myxomas is
unclear, but it should not be attributed only to the presence of
the virus in the tissue. Indeed, we were able to show that the
MV-Serp2 mutant can replicate as efficiently as the wild-type
virus at the inoculation site and in the parotid lymph node. The
comparable level of viral loads between both viruses indicates
that the clinical and histologic differences observed cannot be
attributed simply to a more poorly growing mutant virus. We
were able to show that the lymphocytes in the lymph node of
rabbits infected with the MV-Serp2 mutant are indeed in-
fected.
Our conclusions from these observations are that in the MV,
Serp2 is able to block both the processing of the inflammatory
reaction at an early stage and apoptosis of the lymphocytes. It
seems relevant to associate these phenomena with the inhibi-
tion of caspase 1 and/or another aspartic acid-specific protease.
It was previously reported that inactivation of the crmA gene
of cowpox virus or its equivalent SPI-2 gene of rabbitpox virus
resulted in an attenuation of the clinical course, as measured
by the body weight of mice after intranasal infection (63). How-
ever, the cowpox and rabbitpox viruses differed in the inflam-
matory response. An acute inflammatory response was de-
scribed as associated with disruption of the SPI-2 gene in the
rabbitpox virus, whereas disruption of the open reading frame
on the cowpox virus seemingly resulted in a decreased influx of
inflammatory cells. Using the same murine intranasal model,
other authors have reported that inactivation of the SPI-2 gene
of the vaccinia virus had no effect on virus virulence (31). These
contradictory results concerning three members of the Ortho-
poxvirus genus may be attributed to either true differences in
the viruses or to mutations acquired elsewhere in the genomes,
since neither cowpox nor rabbitpox revertant viruses were pro-
duced (63). However, in each case the mice had been inocu-
lated intranasally. Here, we have been using the intradermal
route, which seems more relevant since rabbits get contami-
nated through fleas or mosquito bites (20). It is also unlikely
that mutations acquired elsewhere in the genome are respon-
sible for our results since restoration of the wild-type pheno-
type was observed with the revertant virus. So we can state that
what we describe here truly reflects the role of Serp2 during
the course of a natural infection.
The actual targets of Serp2 in vivo have not been found yet.
Indeed, in previous experiments we were able to visualize a
complex between Serp2 and human ICE, and the processing of
pro-IL-1 by ICE was inhibited by Serp2 produced in a bacu-
lovirus expression system (46). It is also reported, however,
that CrmA can form a complex with ICE (caspase 1) (50),
Cpp32 (caspase 3), FLICE (caspase 8), and Mch2 (caspase 6)
(72); CrmA also has some inhibitory effect upon these four
proteases (33, 72). However, kinetics analysis indicates that
caspase 1 and caspase 8, but not caspase 3 and caspase 6, are
direct targets of CrmA in vivo (72).
It has recently been demonstrated that, although the prod-
ucts of SPI-2 and crmA were thought to be equivalent, these
two serpins actually have distinct effects on the caspases (36).
Both proteins can block ICE activity in vitro (36). However,
SPI-2 is unable to prevent apoptosis in pig kidney cells, where-
as CrmA is a potent inhibitor. These results suggest that SPI-2
and CrmA have different targets in vivo.
It is likely that, like CrmA, Serp2 has more than one target.
Our in vivo data support the hypothesis that ICE is one of
them. Unlike CrmA and SPI-2, which are only expressed early
during infection, Serp2 is expressed both at early and late times
(46). It is not surprising that its extra target(s) might be dif-
ferent from those of CrmA or SPI-2.
There is currently a better knowledge of the viral genetic
functions important for the pathogenesis of the leporipoxvirus
genus, and several factors have been characterized to date.
These include the MV TNF receptor (68); the IFN- receptor
homolog (69); M-T5, which is a member of the host range
superfamily (39); M11L and myxoma growth factor (MGF)
(45); SERP-1, which is a serpin-like protein that interferes with
inflammation (34, 67); and M-T1, a 35-kDa protein recently
described as a chemokine-binding protein (25). Serp2 appears
as a critical component of the immune evasion strategy elicited
by MV. Further dissection of the multiple consequences of the
inhibition of ICE and/or other caspases by Serp2 will be infor-
mative regarding the relative importance of inflammation and
apoptosis for eliminating the virus.
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